Work packages 6 - 10
Lead beneficiary : NOX
Nox Medical is an industrial leader in sleep diagnostic equipment. The Sleep Revolution works together with Nox Medical to provide and validate a new concept of multiple night home Self-Applied-Somnograph (SAS) studies instead of the current clinical gold standard; a complex single night in-lab Polysomnography (PSG). This opens for the possibility to transfer diagnostic procedure to the patient’s home.
Lead beneficiary : RU
Work-package 7 focuses on the design and development of a state-of-the art digital platform that connects participants with healthcare professionals and research co-ordinators. The digital platform functions as a bridge between different stakeholder groups. These stakeholder groups are mainly healthcare providers, and participants in various research studies linked to the Sleep Revolution project and the digital platform that we are designing and developing has the potential to become the leading digital platform for connecting healthcare providers and recipients in Europe.
Lead beneficiary : UGOT
This work package will validate the new diagnostic and therapeutic algorithms developed in the Sleep Revolution project so far. A prospective study will include 1000 patients in the European Sleep Apnea Database network of 24 sleep centers across Europe. To start we need a finalized clinical study protocol and an approval from the ethical review board in all centers of the ESADA. Thereafter 1000 patients will be randomized to standard care according to the different routines in the ESADA centers or the new diagnostic pathways of the “Sleep Revolution” Project.
Lead beneficiary : A-HUS
The main aims of this work package are to study the effect of and adherence to orofacial myofunctional therapy (OMT) in motivated patients with mild to moderate sleep apnea. Participants will be recruited among patients referred to the Ear-Nose-Throat Department's of Ahus and the university hospital in Tartu, Estonia. Patients will be randomized to either following active treatment or placebo. All participants will receive a three day sleep test and clinical examination at the beginning of the study and after 3 months of treatment.
Lead beneficiary : RU
What are we researching in WP 10: The sample will be formed by 200 clinical participants, aged 18-40. It is aimed to include 80 women and 120 men. Inclusion criteria are a BMI ≥ 25, physical inactivity, and a diagnosis of mild sleep-disordered breathing (SDB) which does not fulfill criteria for positive airway pressure therapy. Therefore, SDB level may range from habitual snoring to positional and mild obstructive sleep apnea (OSA).